CDEK
← All organizations

Bridge Biotherapeutics, Inc.

For profitWebsite ↗

Also known as: Bridge Biotherapeutics, Inc. | ORIGIN | VP Clinical Development, CoA Therapeutics, Inc., a Bridgebio company

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 2

First clinical trial

Mar 20, 2018

First marketed drug

Feb 26, 2021

Last known activity

Sep 11, 2023

Timeline

2010s

  1. Jun 1, 2015

    Bridge Biotherapeutics, Inc.— Founded

2020s

  1. Oct 5, 2020

    Eidos Therapeutics, Inc.— Acquired

  2. Feb 26, 2021

    Fosdenopterin— Marketing Organization

Drugs by trial phase (11 distinct, 21 trials)

Phase 3 (0 own, 1 via acquisition)

Phase 2 (5 own, 1 via acquisition)

Phase 1 (4 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (16)

Details

Founded
Seongnam, KR Jun 1, 2015
Last known activity
Sep 11, 2023